Latest Headlines

Latest Headlines

Sun has terrific quarter, except for that Pfizer thing

Sun's sales in the U.S. were up 28%, and it posted a profit of $204.8 million for the quarter--that is, before that one thing with Pfizer. Of course, that one thing was a 25.2 billion rupee payment ($415 million) that it made to Pfizer and Takeda as part of its share of a $2.15 billion settlement it and Teva Pharmaceutical Industries reached with the two.

Credit Suisse says Pfizer patent win will discourage 'at-risk' launches

Will Pfizer's big patent win against Teva Pharmaceutical Industries and India's Sun Pharma on Protonix discourage more "at-risk" drug launches of generics in the U.S.?

Teva loses $2B gamble on generic of Pfizer's Protonix

When Teva Pharmaceutical Industries launched a generic version of Protonix in 2007 before its patent expiration, it set aside $670 million to compensate Pfizer for lost profits on the drug. But with a settlement announced today, the company is finding itself $1.6 billion short.

Teva's at-risk Protonix launch could cost $2B-plus

Turns out, Teva Pharmaceutical Industries' ($TEVA) at-risk launch of copycat Protonix was really, really risky. The company now says it's looking at up to $2 billion in legal losses, to compensate Pfizer ($PFE) for lost profits on the drug.

Pfizer to pay $55M to clean Wyeth's dirty laundry

Another marketing settlement has been wrung out of a Big Pharma player, with Pfizer ($PFE) this time paying $55 million and change to clear up a problem it acquired.

Pfizer racks up $600M-plus in Wyeth-related legal settlements

Pfizer ($PFE) has racked up a trifecta of legal deals, from a $55 million Protonix settlement with the feds to a $491 million Rapamune marketing deal that involves a misdemeanor guilty plea. Sandwiched in the middle: A $67.5 million deal to wrap up a class-action lawsuit filed by former Wyeth shareholders, who claimed they were misled about the risks of its antidepressant Pristiq.

Wyeth puts $960M squeeze on Sun for Protonix launch

Sun Pharmaceuticals ' at-risk launch of generic Protonix may prove to have been risky indeed. Pfizer's ($PFE) Wyeth unit slapped the Indian drugmaker with a $960 million damages claim, alleging Sun's

Public Citizen asks FDA for black box on PPIs

Public Citizen is petitioning the FDA for a "black box" warning on common stomach acid drugs such as AstraZeneca's ($AZN) Nexium and Prilosec and Pfizer's ($PFE) Protonix. The consumer watchdog group

Pfizer in talks with feds on Protonix rebate charges

Pfizer ($PFE) is negotiating with the U.S. government to settle claims that it overcharged Medicaid for the stomach drug Protonix, Pharmalot reports, citing legal documents filed in a Boston federal

Nycomed eyes emerging markets boost to 60% of sales

Nycomed execs are following their Big Pharma brethren in promising big growth in emerging markets. They're also echoing the bigger drugmakers with laments about losing sales to new generic